Sunil Healthcare manufactures empty hard gelatin and HPMC capsule shells used by pharmaceutical and food supplement companies to package and deliver their products. The company operates a manufacturing facility in Rajasthan and sells its products to both domestic and international markets.
The company operates in a commoditized segment of the pharmaceutical supply chain where it lacks pricing power, as evidenced by net margins averaging below 2% and a negative EPS CAGR. While they possess technical certifications like WHO-GMP, the low ROCE of 9.2% suggests no durable competitive advantage or scale-based cost edge.
Capital has been deployed toward capacity expansion from 13 billion to 15 billion units, yet these investments have failed to generate meaningful shareholder value, with EPS declining sharply and ROE remaining a meager 5.1%. The company has suspended dividends to fund growth that has not yet translated into bottom-line results.
The company's aggressive capacity expansion from 13 to 15 billion units failed to offset its lack of pricing power in a commoditized market. As interest rates remained elevated, the negative interest coverage ratio and high debt-to-equity levels led to a liquidity crunch, forcing the business to liquidate assets at a loss. The combination of shrinking earnings and high promoter remuneration drained the remaining cash reserves, leaving shareholders with a hollowed-out shell of a business that could no longer service its obligations.
RichFakir rates Sunil Healthcare Ltd's business quality as poor — 22/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sunil Healthcare Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sunil Healthcare Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now. We marked it down a notch: revenue and earnings barely grow — a steady cash cow, not a compounder.
RichFakir's educational estimate of Sunil Healthcare Ltd's fair value is about ₹23 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →